Although all unimolecular triple agonists in phase 2 trials for obesity are GLP1/GIP/GCG triple agonists, there is an ongoing phase 2 clinical trial of bioglutide, an oral insulin-like-growth factor-1 (IGF-1)/GLP-1/GIP/GCG quadruple agonist (NCT06564753) for individuals with obesity, which is also being trialled in combination with tirzepatide (NCT06643728)
A p-value .05)
So far, dizziness is listed as a less common side effect in prescribing information
By the time we reach our late 20s, natural production often begins to decline, which is why many people start to feel the "slow down" of early middle age
According to the MHRA-approved Summary of Product Characteristics (SmPC), the most commonly reported side effects of semaglutide include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort
My hair started to fall out, my nails kept breaking off, and my bowels cramped every time I ate